A detailed history of Capital International, Inc. transactions in Bio N Tech Se stock. As of the latest transaction made, Capital International, Inc. holds 930,474 shares of BNTX stock, worth $109 Million. This represents 1.46% of its overall portfolio holdings.

Number of Shares
930,474
Previous 198,890 367.83%
Holding current value
$109 Million
Previous $16 Million 591.48%
% of portfolio
1.46%
Previous 0.22%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$78.36 - $124.66 $57.3 Million - $91.2 Million
731,584 Added 367.83%
930,474 $111 Million
Q2 2024

Aug 13, 2024

BUY
$80.36 - $102.87 $15 Million - $19.2 Million
187,057 Added 1580.81%
198,890 $16 Million
Q1 2024

May 14, 2024

SELL
$88.96 - $112.35 $35,317 - $44,602
-397 Reduced 3.25%
11,833 $1.09 Million
Q4 2023

Feb 13, 2024

BUY
$90.91 - $112.75 $100,364 - $124,476
1,104 Added 9.92%
12,230 $1.29 Million
Q3 2023

Nov 13, 2023

BUY
$98.5 - $125.08 $146,568 - $186,119
1,488 Added 15.44%
11,126 $1.21 Million
Q2 2023

Aug 11, 2023

BUY
$102.58 - $129.66 $127,301 - $160,908
1,241 Added 14.78%
9,638 $1.04 Million
Q4 2022

Feb 14, 2023

SELL
$118.43 - $186.05 $41,687 - $65,489
-352 Reduced 4.02%
8,397 $1.26 Million
Q3 2022

Nov 14, 2022

BUY
$127.65 - $183.11 $1.12 Million - $1.6 Million
8,749 New
8,749 $1.18 Million
Q1 2022

May 16, 2022

SELL
$126.25 - $231.85 $1.77 Million - $3.25 Million
-14,036 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$205.93 - $447.23 $1.36 Million - $2.94 Million
-6,582 Reduced 31.92%
14,036 $3.83 Million
Q2 2021

Aug 16, 2021

BUY
$113.32 - $241.49 $954,494 - $2.03 Million
8,423 Added 69.07%
20,618 $4.62 Million
Q1 2021

May 14, 2021

BUY
$85.73 - $119.5 $1.05 Million - $1.46 Million
12,195 New
12,195 $1.33 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $28.5B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Capital International, Inc. Portfolio

Follow Capital International, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital International, Inc. with notifications on news.